- CA$130.80m
- CA$170.26m
- $55.50m
Brief: HLS Therapeutics Q2 Loss Per Share $0.20
Brief: HLS Therapeutics Inc - Reaffirms Peak-Year Sales Forecast For Vascepa
Brief: HLS Therapeutics Becomes Exclusive Canadian Distributor For Mycare Insite Point-Of-Care Device
Brief: HLS Therapeutics Supports Trial To Investigate Effects Of Vascepa Against COVID-19
Canada Research Roundup: Cargojet, Kinaxis, Silvercrest Metals
Brief: HLS Therapeutics Comments On U.S. District Court Decision On Amarin Patents
Canada Research Roundup: Cineplex, Northland Power, Transalta Renewables
Brief: Hls Therapeutics Announces Qtrly Loss Per Share $0.40
Brief: Hls Therapeutics Provides Investor Update On The Canadian Launch Of Vascepa®
Brief: HLS Therapeutics Files New Drug Submission For Perseris In Canada
Brief: HLS Therapeutics Announces Health Canada Approval For Vascepa To Reduce Risk Of Cardiovascular Events
Canada Research Roundup: Altagas, George Weston, HLS Therapeutics
Canada Stocks: TSX futures rise on hopes of U.S.-China trade deal
Brief: HLS Therapeutics Qtrly Loss Per Share $0.06
Brief: HLS Therapeutics Q2 Loss Per Share $0.06
Indivior signs deal to sell schizophrenia drug in Canada
Brief: Hls Therapeutics Q1 Loss Per Share $0.14
Brief: Indivior Enters Into Exclusive License Agreement With HLS Therapeutics For Perseris
Brief: HLS Therapeutics Files New Drug Submission for Vascepa in Canada